BACKGROUND: Alternate waiting list strategies expand listing criteria for patients awaiting heart transplantation (HTx). We retrospectively analyzed clinical events and outcome of patients listed as high-risk recipients for HTx. METHODS AND RESULTS: We analyzed 822 adult patients who underwent HTx of whom 111 patients met high-risk criteria. Clinical data were collected from medical records and outcome factors calculated for 61 characteristics. Significant factors were summarized in a prognostic score. Age >65 years (67%) and amyloidosis (19%) were the most common reasons for alternate listing. High-risk recipients were older (63.2±10.2 versus 51.4±11.8 years; P<0.001), had more renal dysfunction, prior cancer, and smoking. Survival analysis revealed lower post-HTx survival in high-risk recipients (82.2% versus 87.4% at 1-year; 59.8% versus 76.3% at 5-year post-HTx; P=0.0005). Prior cerebral vascular accident, albumin <3.5 mg/dL, re-HTx, renal dysfunction (glomerular filtration rate <40 mL/min), and >2 prior sternotomies were associated with poor survival after HTx. A prognostic risk score (CARRS [CVA, albumin, re-HTx, renal dysfunction, and sternotomies]) derived from these factors stratified survival post-HTx in high-risk (3+ points) versus low-risk (0-2 points) patients (87.9% versus 52.9% at 1-year; 65.9% versus 28.4% at 5-year post-HTx; P<0.001). Low-risk alternate patients had survival comparable with regular patients (87.9% versus 87.0% at 1-year and 65.9% versus 74.5% at 5-year post-HTx; P=0.46). CONCLUSIONS: High-risk patients had reduced survival compared with regular patients post-HTx. Among patients previously accepted for alternate donor listing, application of the CARRS score identifies patients with unacceptably high mortality after HTx and those with a survival similar to regularly listed patients.
BACKGROUND: Alternate waiting list strategies expand listing criteria for patients awaiting heart transplantation (HTx). We retrospectively analyzed clinical events and outcome of patients listed as high-risk recipients for HTx. METHODS AND RESULTS: We analyzed 822 adult patients who underwent HTx of whom 111 patients met high-risk criteria. Clinical data were collected from medical records and outcome factors calculated for 61 characteristics. Significant factors were summarized in a prognostic score. Age >65 years (67%) and amyloidosis (19%) were the most common reasons for alternate listing. High-risk recipients were older (63.2±10.2 versus 51.4±11.8 years; P<0.001), had more renal dysfunction, prior cancer, and smoking. Survival analysis revealed lower post-HTx survival in high-risk recipients (82.2% versus 87.4% at 1-year; 59.8% versus 76.3% at 5-year post-HTx; P=0.0005). Prior cerebral vascular accident, albumin <3.5 mg/dL, re-HTx, renal dysfunction (glomerular filtration rate <40 mL/min), and >2 prior sternotomies were associated with poor survival after HTx. A prognostic risk score (CARRS [CVA, albumin, re-HTx, renal dysfunction, and sternotomies]) derived from these factors stratified survival post-HTx in high-risk (3+ points) versus low-risk (0-2 points) patients (87.9% versus 52.9% at 1-year; 65.9% versus 28.4% at 5-year post-HTx; P<0.001). Low-risk alternate patients had survival comparable with regular patients (87.9% versus 87.0% at 1-year and 65.9% versus 74.5% at 5-year post-HTx; P=0.46). CONCLUSIONS: High-risk patients had reduced survival compared with regular patients post-HTx. Among patients previously accepted for alternate donor listing, application of the CARRS score identifies patients with unacceptably high mortality after HTx and those with a survival similar to regularly listed patients.
Authors: Josef Stehlik; Leah B Edwards; Anna Y Kucheryavaya; Paul Aurora; Jason D Christie; Richard Kirk; Fabienne Dobbels; Axel O Rahmel; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2010-10 Impact factor: 10.247
Authors: Mani A Daneshmand; Keshava Rajagopal; Brian Lima; Nikta Khorram; Laura J Blue; Andrew J Lodge; Adrian F Hernandez; Joseph G Rogers; Carmelo A Milano Journal: Ann Thorac Surg Date: 2010-04 Impact factor: 4.330
Authors: Mandeep R Mehra; Jon Kobashigawa; Randall Starling; Stuart Russell; Patricia A Uber; Jayan Parameshwar; Paul Mohacsi; Sharon Augustine; Keith Aaronson; Mark Barr Journal: J Heart Lung Transplant Date: 2006-09 Impact factor: 10.247
Authors: Kimberly N Hong; Alexander Iribarne; Berhane Worku; Hiroo Takayama; Annetine C Gelijns; Yoshifumi Naka; Val Jeevanandam; Mark J Russo Journal: Ann Thorac Surg Date: 2011-06-17 Impact factor: 4.330
Authors: Eric S Weiss; Jeremiah G Allen; George J Arnaoutakis; Timothy J George; Stuart D Russell; Ashish S Shah; John V Conte Journal: Ann Thorac Surg Date: 2011-09 Impact factor: 4.330
Authors: George J Arnaoutakis; Timothy J George; Jeremiah G Allen; Stuart D Russell; Ashish S Shah; John V Conte; Eric S Weiss Journal: J Thorac Cardiovasc Surg Date: 2012-01 Impact factor: 5.209
Authors: Mark J Russo; Ryan R Davies; Kimberly N Hong; Jonathan M Chen; Michael Argenziano; Alan Moskowitz; Deborah D Ascheim; Isaac George; Allan S Stewart; Mathew Williams; Annetine Gelijns; Yoshifumi Naka Journal: Ann Thorac Surg Date: 2009-04 Impact factor: 4.330
Authors: Maryjane Farr; James Mitchell; Matthew Lippel; Tomoko S Kato; Zhezhen Jin; Paul Ippolito; Lorna Dove; Ulrich P Jorde; Hiroo Takayama; Jean Emond; Yoshifumi Naka; Donna Mancini; Jay H Lefkowitch; P Christian Schulze Journal: J Heart Lung Transplant Date: 2014-12-23 Impact factor: 10.247
Authors: Lakshmi Sridharan; Brian Wayda; Lauren K Truby; Farhana Latif; Susan Restaino; Koji Takeda; Hiroo Takayama; Yoshifumi Naka; Paolo C Colombo; Mathew Maurer; Maryjane A Farr; Veli K Topkara Journal: Circ Heart Fail Date: 2018-03 Impact factor: 8.790
Authors: Anuradha Lala; John C Rowland; Bart S Ferket; Annetine C Gelijns; Emilia Bagiella; Sean P Pinney; Alan J Moskowitz; Marissa A Miller; Francis D Pagani; Donna M Mancini Journal: JAMA Cardiol Date: 2020-06-01 Impact factor: 14.676
Authors: Sebastian Claes; Michael Berchtold-Herz; Qian Zhou; Georg Trummer; Matthias Bock; Andreas Zirlik; Friedhelm Beyersdorf; Christoph Bode; Sebastian Grundmann Journal: J Cardiothorac Surg Date: 2017-03-07 Impact factor: 1.637
Authors: Agnieszka Kuczaj; Szymon Pawlak; Piotr Przybyłowski; Szymon Warwas; Joanna E Śliwka; Michał Zakliczyński; Tomasz Hrapkowicz Journal: Ann Transplant Date: 2022-02-22 Impact factor: 1.530
Authors: Benjamin L Shou; Devina Chatterjee; Joseph W Russel; Alice L Zhou; Isabella S Florissi; Tabatha Lewis; Arjun Verma; Peyman Benharash; Chun Woo Choi Journal: J Cardiovasc Dev Dis Date: 2022-09-19